Shares of Marksans Pharma Ltd dropped 3.6% to ₹163.30 in Friday’s session, reacting to U.S. President Donald Trump’s announcement of a 100% tariff on branded and patented pharmaceutical imports, effective October 1, 2025. The move has raised concerns across India’s pharma sector, given its heavy dependence on the American market.
Trump stated that the tariffs will not apply to companies already “building” manufacturing plants in the U.S., defined as projects either breaking ground or under construction. While primarily aimed at multinational drugmakers, the uncertainty over complex generics and specialty drugs has weighed on investor sentiment for Indian firms like Marksans.
Marksans Pharma exports extensively to the US, which is a key growth market for the company. The company supplies a wide range of generic prescription and private-label Over-The-Counter (OTC) products, including medications for pain management, gastrointestinal issues, and cold/cough. Its U.S. strategy is driven by its subsidiary, Time-Cap Labs (TCL), which manufactures solid-dose generic products, with a continued focus on transitioning to OTC medications.
India supplies nearly 45% of U.S. generic demand and earns a significant share of revenues from exports to America. With Trump also imposing tariffs on furniture, trucks, and kitchen goods, the protectionist stance is expected to ripple across multiple Indian export-linked sectors.
At the time of writing, Marksans Pharma was down ₹6.09 from its previous close of ₹169.39, underperforming the broader market.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
